Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19013827 | 0.82 | AKR1C3 (0.55) | ACHEMEN1KMT2AALDH1A1HSD11B1 | |
| SCHEMBL19640886 | 0.82 | AKR1C3 (0.52) | ACHEMEN1KMT2AALDH1A1HSD11B1 | |
| SCHEMBL2220869 | 0.80 | TRPA1 (0.53) | ACHEALDH1A1KDM2BCYP3A4AKR1C3 | |
| SCHEMBL2221604 | 0.79 | MEN1 (0.53) | ACHEMEN1KMT2AAKR1C3PSEN1 | |
| SCHEMBL2221432 | 0.77 | PSEN1 (0.72) | ACHEMEN1KMT2AALDH1A1KDM2B | |
| SCHEMBL2221744 | 0.77 | ACHE (0.50) | ACHEMEN1KMT2AALDH1A1AKR1C3 | |
| SCHEMBL8327339 | 0.75 | EPHX2 (0.45) | ACHEMEN1KMT2AALDH1A1HSD11B1 | |
| SCHEMBL2221418 | 0.75 | ACHE (0.49) | ACHEMEN1KMT2AHSD11B1AKR1C3 | |
| SCHEMBL15009887 | 0.75 | ALDH1A1 (0.77) | MEN1KMT2AALDH1A1HSD11B1GAA | |
| SCHEMBL2220964 | 0.75 | PSEN1 (0.70) | ACHEMEN1KMT2AALDH1A1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | claimed |
| EP-1915371-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2008-04-30 | — | — | EP | claimed |
| WO-2007024651-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | claimed |
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-1915371-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007024651-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | ACHE 17/4885MEN1 2563/4885KMT2A 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.